Form 144 Filer Information UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

Form 144

144: Issuer Information

Name of Issuer
Keros Therapeutics, Inc.
SEC File Number
001-39264
Address of Issuer
1050 WALTHAM STREET, SUITE 302
LEXINGTON
MASSACHUSETTS
02421
Phone
617-314-6297
Name of Person for Whose Account the Securities are To Be Sold
The Biotech Growth Trust PLC
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer
  1. Shareholder

144: Securities Information


RecordTitle of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
#1Common Stock
Evercore ISI
55 East 52nd Street
New York
NEW YORK
10055
170,000$7,461,300.0029,584,17306/12/2023
Nasdaq Stock Market

144: Securities To Be Sold

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

RecordTitle of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
#1Common Stock03/02/2020Private placementIssuer☐ — 170,00003/02/2020Cash


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

144: Securities Sold During The Past 3 Months

Nothing to Report☒

144: Remarks and Signature

Remarks
OrbiMed Capital LLC is the portfolio manager of The Biotech Growth Trust PLC.
Date of Notice
06/12/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature
/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Capital LLC, portfolio manager of The Biotech Growth Trust PLC

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni Keros Therapeutics (NASDAQ:KROS)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Keros Therapeutics
Grafico Azioni Keros Therapeutics (NASDAQ:KROS)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Keros Therapeutics